3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, Large B-Cell, Diffuse
85
Lymphoma, Follicular
53
Lymphoma
50
Lymphoma, Non-Hodgkin
47
Lymphoma, Mantle-Cell
46
Lymphoma, B-Cell, Marginal Zone
45
Leukemia, Lymphocytic, Chronic, B-Cell
40
Lymphoma, B-Cell
31
Recurrence
20
Burkitt Lymphoma
20
Waldenstrom Macroglobulinemia
16
Precursor Cell Lymphoblastic Leukemia-Lymphoma
16
Neoplasms
16
Leukemia
11
Leukemia, Hairy Cell
7
Lymphoproliferative Disorders
5
Hodgkin Disease
5
Hematologic Neoplasms
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Myelodysplastic Syndromes
4
Leukemia, Myeloid, Acute
4
Hematologic Diseases
4
Dendritic Cell Sarcoma, Interdigitating
4
Neoplasm, Residual
3
Lymphoma, AIDS-Related
3
Leukemia, Myeloid, Accelerated Phase
3
Leukemia, Biphenotypic, Acute
3
Epstein-Barr Virus Infections
3
beta-Thalassemia
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Interventions
Carboplatin
6
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
130-nm albumin-bound paclitaxel
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Rituximab
×
1 year
×
Clear all
No trials found.